Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R- transplant recipients

BACKGROUND: Valganciclovir, the oral prodrug of ganciclovir, has been demonstrated equivalent to iv ganciclovir for CMV disease treatment in solid organ transplant recipients. Variability in ganciclovir exposure achieved with valganciclovir could be implicated as a contributing factor for explaining...

Descripción completa

Detalles Bibliográficos
Autores principales: Perrottet, Nancy, Manuel, Oriol, Lamoth, Frédéric, Venetz, Jean-Pierre, Sahli, Roland, Decosterd, Laurent A, Buclin, Thierry, Pascual, Manuel, Meylan, Pascal
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2820479/
https://www.ncbi.nlm.nih.gov/pubmed/20053269
http://dx.doi.org/10.1186/1471-2334-10-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2820479/
https://www.ncbi.nlm.nih.gov/pubmed/20053269
http://dx.doi.org/10.1186/1471-2334-10-2

Ejemplares similares